Skip to main content
. 2019 Aug 31;142(10):3009–3027. doi: 10.1093/brain/awz232

Figure 6.

Figure 6

Effects of FDA-approved NMDAR channel blockers on wild-type and mutant GluN1/GluN2D receptors. Composite concentration-response curves of FDA-approved NMDAR antagonists were evaluated by TEVC recordings from Xenopus oocytes in the presence of 100 μM glutamate and 100 μM glycine at holding potential of −40 mV. (A) memantine, (B) dextromethorphan, (C) dextrorphan, and (D) ketamine. Data are mean ± SEM. Smooth curves are Equation 2 fitted to the data.